Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A user reversed severe hair loss with dieting, lifestyle changes, and topical minoxidil, highlighting reduced inflammation and body fat. The conversation debates finasteride's effectiveness and the impact of diet and lifestyle on hair health.

The user has been dealing with hair loss for 10 years, worsened by psoriasis, and uses minoxidil and finasteride. They seek advice on managing psoriasis and hair loss, with suggestions to see a dermatologist, try different shampoos, and be patient.

Creatine is unlikely to worsen hair loss for those on finasteride, with no strong scientific evidence linking it to increased hair loss. Many users report no negative effects on hair while using creatine.

Quitting vaping significantly reduced hair loss for a user who was a heavy vaper and also taking finasteride. Some participants suggest nicotine's vasoconstrictive properties may worsen hair loss, while others share personal anecdotes of hair improvement after quitting smoking or vaping.

User discusses resentment towards people who dismissed their hair loss concerns and continued to do so even after a specialist confirmed it. Others share similar experiences and discuss the impact of hair loss on self-esteem and societal perceptions.

User Basic_Football999 discusses concerns about negative dutasteride experiences. Replies suggest dutasteride is effective, but some users may have issues with dosing frequency or genetic factors affecting results.

A 24-year-old person who is worried about their hair loss after 14 months of taking finasteride and 11 months of minoxidil. Replies to the post suggested sticking with their current regimen, that shedding from one part may not be telogen effluvium, and that shedding is normal with these drugs and they should evaluate in two to three months.

User tried DIY Dutasteride Mesotherapy for hair loss due to unsatisfactory Finasteride results. Used mesotherapy injection gun and liquid dutasteride for better results and fewer side effects.

A 31-year-old man has been using Dutasteride since 2022, alongside topical Minoxidil, with positive results and no issues. His new healthcare provider expressed concerns about long-term Dutasteride use and suggested alternatives like oral Minoxidil and Spironolactone, but the patient is hesitant to change a successful routine.

The user experienced significant hair regrowth using a single pill containing 2.5mg minoxidil and 1mg finasteride over 11 months, with noticeable improvements starting around month 8. They reported minor side effects initially but none ongoing, and they have not undergone a hair transplant.

Creatine use with finasteride increased DHT levels, possibly affecting hair loss. The user plans to reduce creatine to stabilize DHT and hair shedding.

Stopping finasteride increased sex drive for some, while others had no change or different side effects. Despite concerns, many continue using finasteride for its effectiveness in preventing hair loss.

A 24-year-old shared his 13-month experience using 1mg oral finasteride and 5mg oral minoxidil, along with topical minoxidil and ketoconazole shampoo, for hair regrowth with impressive results and no significant side effects. He advises consulting a dermatologist before starting a similar routine.

Gym and creatine can cause hair loss by increasing testosterone and androgenic activity. DHT blockers may help some, while others need androgen suppression with topical AA like RU or Pyri.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

The conversation is about a user's hair loss treatment regimen, which includes Dutasteride, oral Minoxidil, topical Dutasteride, Minoxidil sulfate, antioxidants, and various supplements. The user is also using a derma stamp and has paused Tretinoin due to a TCA peel recovery.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.

Finasteride, minoxidil, and derma rolling are currently the best treatments for hair loss. New treatments like TDM-105795, GT20029, PP405, HMI 115, Tsuji, Scube 3, RU, JW0061, Topilutamide, and verteporfin show promise but have uncertain timelines.

PP405 trials have completed phase 2a, showing promising results with a 31% stat for hair density increase, and are moving directly to phase 3. Detailed results will be presented at a medical conference in 2026.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.

The user is using a hair loss treatment involving dutasteride, minoxidil, finasteride, microneedling, and supplements like multivitamins, D3 K2, and Omega 3 fish oil. They are considering adding tretinoin and are open to suggestions while managing gut issues.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

A 25-year-old woman with androgenic alopecia is experiencing hair dryness and damage after using topical minoxidil and Nizoral. She is advised to reduce washing frequency, use a bond builder like K18, apply a silicone-based serum, and consider using a shower filter and different oils like argan oil for better hair health.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.